Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Prosthesis-patient mismatch (PPM) after TAVR

Cardiologists may want to rethink how they track prosthesis-patient mismatch after TAVR

Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice. 

Thumbnail

Downstream costs of noninvasive cardiac diagnostics revealed in data study

At what looks to be an 18% cost savings downstream, stress echocardiograms looks to be the least expensive diagnostic procedure for patients with chest pain

cannabis use disorder marijuana joint weed smoking

Daily marijuana use increases heart failure risk by 34%

“Marijuana use isn’t without its health concerns, and our study provides more data linking its use to cardiovascular conditions," one researcher said. 

CVD deaths have increased dramatically, undoing years of progress

The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all? 

Thumbnail

TAVR linked to favorable outcomes for asymptomatic and minimally symptomatic patients—but is it necessary?

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.

Women in rural areas, especially racial minorities, are less likely to receive a mammogram

A study looking at older Medicare beneficiaries in Texas highlights a need for targeted breast cancer screening outreach.

Thumbnail

Cardiologist reprimanded for performing surgery after testing positive for COVID-19

He has agreed to pay an administrative fee of $1,100 within the next three months.

A closer look at how weight loss drug semaglutide improves the cardiovascular health of obese patients without diabetes

Novo Nordisk shared initial results from the SELECT trial back in August, but now the full analysis—which includes data from more than 17,000 patients—has been published in The New England Journal of Medicine.